Eloralintide 5mg Vial – Research Peptide UK

Eloralintide 5mg is a synthetic research peptide associated with LY3841136, an investigational selective amylin receptor agonist developed by Eli Lilly. The compound is attracting significant scientific interest because of its distinctive receptor activity and its potential role in the study of appetite signalling, satiety and metabolic regulation. Eloralintide represents an emerging area of peptide research, with published Phase 2 findings and ongoing Phase 3 clinical development. Its activity at the amylin receptor makes it scientifically distinct from conventional GLP-1 receptor agonists. The Eloralintide 5mg Vial is listed by N&A Peptides for legitimate laboratory and analytical research purposes only. The compound remains investigational and is not approved for human or veterinary use.

What Is Eloralintide (LY3841136)?

Eloralintide, also identified as LY3841136, is an investigational long-acting amylin receptor agonist. It has been studied by Eli Lilly as part of its research into metabolic signalling and weight regulation. Amylin is a naturally occurring peptide hormone secreted by pancreatic beta cells alongside insulin. It participates in biological processes involving satiety, gastric emptying and post-meal glucose regulation. Amylin receptors are formed through interactions between calcitonin receptor proteins and receptor activity-modifying proteins. Eloralintide has a selective pharmacological profile, with particular interest in its activity at the amylin-1 receptor, commonly identified as AMY1R. Researchers investigate how selective receptor activation may influence intracellular signalling, receptor response, pharmacodynamics and broader metabolic pathways.

Eloralintide 5mg Research Applications

Eloralintide 5mg is relevant to scientific investigations involving amylin-associated biological pathways. Current areas of research interest include:

• Selective amylin receptor activation
• AMY1R receptor signalling
• Peptide and receptor binding interactions
• Metabolic signalling mechanisms
• Appetite and satiety pathways
• Energy balance and metabolic regulation
• Hormone and receptor interactions
• Comparative peptide pharmacology
• Amylin and incretin pathway relationships
• Analytical peptide characterisation

These are areas of scientific investigation, not established therapeutic applications of the research material offered on this page.

How Does Eloralintide Work?

Eloralintide is designed to activate amylin receptors, with selectivity towards the AMY1R receptor subtype. The amylin signalling system contributes to biological mechanisms that regulate fullness and food intake. Amylin-related pathways differ from those primarily activated by glucagon-like peptide-1 (GLP-1) receptor agonists. This distinction has made selective amylin agonists an important subject in modern metabolic research. Scientists are investigating whether differences in receptor selectivity affect biological activity, tolerability, metabolic responses and interactions with other hormonal pathways. The long-acting design of eloralintide is also relevant to research examining peptide pharmacokinetics and pharmacodynamic responses.

Eloralintide Clinical Trials and Scientific Findings

One of the most important developments in eloralintide research was the publication of a 48-week Phase 2 randomised, double-blind, placebo-controlled clinical trial in The Lancet. The study enrolled 263 adults with obesity or overweight and at least one weight-related complication, without type 2 diabetes. Researchers investigated different eloralintide treatment regimens and assessed changes in body weight, safety and tolerability.

Published Phase 2 Research Results

The published study reported the following estimated mean changes in body weight after 48 weeks:

• 1mg study group: Approximately 9% reduction
• 3mg study group: Approximately 12% reduction
• 6mg study group: Approximately 18% reduction
• 9mg study group: Approximately 20% reduction
• Placebo group: Approximately 0.4% reduction

These findings relate exclusively to the published controlled clinical study. The study included specified treatment regimens, with some participants undergoing dose escalation. The highest studied maintenance dose was 9mg; it was not the universal starting dose. These clinical outcomes must not be interpreted as expected results from the Eloralintide 5mg research vial offered by N&A Peptides. Scientific reference: Eloralintide: 48-Week Phase 2 Randomised Clinical Trial – The Lancet / PubMed.

Eloralintide and Tirzepatide Research

Another important area of investigation involves eloralintide in combination with tirzepatide, an established dual GIP and GLP-1 receptor agonist. Eli Lilly announced Phase 2b findings in September 2026 from a controlled clinical study evaluating the investigational combination known as EloraTZP. In that study, the highest reported combination group achieved an average body-weight reduction of 23.3% over 48 weeks, compared with 14.8% in the tirzepatide 15mg comparator group. This was an investigational clinical trial involving specifically controlled treatment protocols. The results do not demonstrate the safety or effectiveness of independently combining research compounds. Read the official Eli Lilly EloraTZP Phase 2b research announcement.

Eloralintide vs Cagrilintide – Research Comparison

Eloralintide and cagrilintide are both investigational compounds associated with amylin signalling research. However, they have different pharmacological profiles and should not be considered interchangeable. Eloralintide has been developed with a selective amylin receptor profile, particularly involving AMY1R activity. Cagrilintide is a long-acting amylin analogue with a different receptor activity profile. Comparative research examines differences in receptor interactions, cellular signalling, pharmacokinetics and responses observed in experimental systems. Researchers interested in comparing amylin-related compounds can also explore our Cagrilintide 5mg Research Pen.

Eloralintide 5mg Vial Product Specifications

• Product: Eloralintide 5mg Vial
• Compound: Eloralintide
• Alternative identifier: LY3841136
• Nominal quantity: 5mg
• Format: Research vial
• Compound category: Investigational peptide
• Research classification: Selective amylin receptor agonist
• Primary receptor interest: AMY1R
• Research focus: Metabolic and receptor signalling
• Supplier: N&A Peptides UK
• Intended use: Laboratory research only

Batch identity, measured content, purity and analytical characteristics should be assessed using the relevant batch documentation where available.

Peptide Purity Testing and Certificates of Analysis

Analytical verification is an important component of responsible peptide research. Laboratory methods such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) can assist in evaluating sample composition, peptide identity and associated impurities. HPLC is frequently used to investigate chromatographic purity and separate sample components. Mass spectrometry provides information relating to molecular mass and can support compound identification. A Certificate of Analysis (COA) may include sample identification, batch information, analytical methods, reported purity and testing dates. Researchers should understand that chromatographic purity alone does not confirm sterility, endotoxin status, accurate vial content or suitability for administration. Explore the N&A Peptides Certificate of Analysis section for available analytical documentation. An Eloralintide-specific COA should only be associated with this listing when the correct batch has been verified.

Eloralintide 5mg Laboratory Storage and Handling

Research peptide stability can be affected by environmental conditions including heat, light, moisture, oxidation and repeated temperature changes. Laboratories should consult the relevant product-specific handling instructions and supporting stability information when determining appropriate conditions for their research materials. Suitable research handling includes maintaining clear batch records, preventing sample contamination and using validated analytical procedures appropriate to the experimental application. Preparation methods, solvents and storage conditions should be determined by qualified laboratory personnel using appropriate scientific documentation rather than assumed from unrelated peptide products.

Eloralintide 5mg Frequently Asked Questions

What is Eloralintide 5mg?

Eloralintide 5mg refers to a nominal 5mg quantity of the investigational peptide LY3841136, which is being studied for its selective activity at amylin receptors.

Is eloralintide the same as retatrutide?

No. Eloralintide is an investigational selective amylin receptor agonist. Retatrutide is an investigational triple receptor agonist associated with GLP-1, GIP and glucagon receptor activity. The compounds act through different pharmacological mechanisms.

Is eloralintide a GLP-1 receptor agonist?

No. Eloralintide is principally investigated as a selective amylin receptor agonist. Its receptor activity differs from GLP-1 medicines and experimental GLP-1 receptor compounds.

Is eloralintide the same as cagrilintide?

No. Both are associated with amylin research, but they are distinct investigational compounds with differing receptor pharmacology.

Who developed eloralintide?

Eloralintide was developed by Eli Lilly and Company and is identified in scientific studies by the research code LY3841136.

Has eloralintide completed clinical trials?

Eloralintide has completed a published 48-week Phase 2 clinical study. Additional Phase 3 studies are underway to further evaluate its efficacy and safety.

Is eloralintide approved for human use?

No. Eloralintide remains an investigational compound and is not an approved medicine. Research products offered by N&A Peptides are not intended for human or veterinary administration.

Does a 5mg vial represent a clinical dosage?

No. The nominal vial quantity describes the labelled amount of research material. It does not establish an approved dose, treatment regimen or suitability for clinical use.

Related Research Products and Resources

Explore additional research compounds and educational information from N&A Peptides:

• Browse All Research Peptides
• Explore Research Peptide Vials
• Cagrilintide 5mg Pen
• Laboratory Certificates of Analysis
• Research Peptide FAQs
• N&A Peptides UK Homepage

Additional Scientific References

• The Lancet – Eloralintide Phase 2 Clinical Trial
• Eli Lilly – ENLIGHTEN-2 Phase 3 Study
• Eli Lilly – ENLIGHTEN-6 Research Study
• Eli Lilly – EloraTZP Clinical Research Results

Important Research Use Disclaimer

FOR LABORATORY RESEARCH USE ONLY – NOT FOR HUMAN OR VETERINARY USE. Eloralintide is an investigational compound. It has not been approved as a medicine and is not intended for self-administration, therapeutic use, diagnosis, treatment or prevention of any disease. All references to clinical research describe independent published studies and do not establish the identity, purity, safety or clinical performance of any particular commercial research sample. N&A Peptides is an independent research-product supplier and is not affiliated with, endorsed by or an authorised manufacturer for Eli Lilly and Company.